Pharmacogenomic Study

OTHER16 trials

Sponsors

National Cancer Institute (NCI), University of Chicago, Children's Oncology Group, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, M.D. Anderson Cancer Center

Conditions

Acute Adult T-Cell Leukemia/LymphomaAdult T-Cell Leukemia/LymphomaAdvanced Adult Hepatocellular CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8AnemiaBRAF Gene MutationBiphasic Mesothelioma

Phase 1

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Active, not recruitingNCT01012817

National Cancer Institute (NCI)Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma +2

Start: 2009-11-03End: 2026-08-27Updated: 2025-09-15

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

TerminatedNCT01071564

National Cancer Institute (NCI)Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative +5

Start: 2009-11-30End: 2014-06-30Updated: 2015-04-15

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

TerminatedNCT01281163

National Cancer Institute (NCI)Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive +4

Start: 2011-01-31End: 2013-12-31Updated: 2015-08-27

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

TerminatedNCT01907802

National Cancer Institute (NCI)BRAF Gene Mutation, Hepatic Complication, Renal Failure +1

Start: 2013-08-23End: 2015-12-16Updated: 2018-08-14

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Active, not recruitingNCT02453620

National Cancer Institute (NCI)Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma +2

Start: 2016-02-12End: 2026-09-17Updated: 2026-04-03

Phase 2

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

CompletedNCT00381641

National Cancer Institute (NCI)Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma +16

Start: 2006-08-29End: 2024-12-10Updated: 2025-03-28

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Active, not recruitingNCT01267955

National Cancer Institute (NCI)Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma +4

Start: 2010-12-21End: 2026-07-21Updated: 2026-04-03

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Active, not recruitingNCT02399371

University of ChicagoBiphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma +7

Start: 2015-03-31End: 2026-03-20Updated: 2025-06-11

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active, not recruitingNCT02581930

National Cancer Institute (NCI)Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7

Start: 2016-08-17End: 2026-03-17Updated: 2025-09-08

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

CompletedNCT02631746

National Cancer Institute (NCI)Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma +3

Start: 2017-02-23End: 2019-07-31Updated: 2025-03-14

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

CompletedNCT02717507

Children's Oncology GroupHematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

Start: 2016-04-04End: 2025-03-31Updated: 2025-04-23

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

CompletedNCT03216499

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsRecurrent Glioblastoma

Start: 2017-09-14End: 2020-06-05Updated: 2022-05-09

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

CompletedNCT03370718

M.D. Anderson Cancer CenterMetastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8 +1

Start: 2018-02-26End: 2024-01-12Updated: 2024-12-10

Phase 3

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

CompletedNCT01015833

National Cancer Institute (NCI)Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma AJCC v7 +7

Start: 2010-02-15End: 2018-08-15Updated: 2022-08-04

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruitingNCT02048813

National Cancer Institute (NCI)Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2014-03-10End: 2026-10-09Updated: 2025-11-28

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active, not recruitingNCT02443077

National Cancer Institute (NCI)Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Start: 2016-10-12End: 2026-12-23Updated: 2026-04-03

Related Papers

Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial

Blood2025-11-03

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Blood2024-11-051 citations

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

HemaSphere2024-05-0115 citations

Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.

2024-04-0915 citations

Abstract 3849: Frontline ibrutinib-based therapy enhances CART cell functions in patients with CLL: Analysis of the phase 3 randomized clinical trial ECOG-ACRIN E1912

Cancer Research2024-03-22

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.

2024-02-1431 citations

Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.

2024-01-0921 citations

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Blood2023-11-02

Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.

Journal of Clinical Oncology2023-06-019 citations

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Blood2022-11-1510 citations

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

Clinical Hematology International2022-09-1414 citations

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

HemaSphere2022-06-011 citations

KDR genetic predictor of toxicities induced by sorafenib and regorafenib.

2022-04-285 citations

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood2022-04-15216 citations

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.

2022-02-077 citations

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with <i>TP53</i> aberrations: a pooled analysis from four clinical trials

British Journal of Haematology2021-12-0561 citations

Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS).

Journal of Clinical Oncology2021-05-201 citations

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)

Melanoma Research2021-03-0411 citations

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Journal of Clinical Oncology2021-01-202 citations

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

Journal of Clinical Oncology2021-01-1331 citations

25 more papers not shown